PubRank

L Devizzi

Author PubWeight™ 19.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2007 2.85
2 Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997 1.61
3 Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 2000 1.42
4 Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000 1.39
5 Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007 1.13
6 Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000 1.08
7 Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996 1.00
8 Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2010 0.88
9 High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2008 0.85
10 Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2009 0.80
11 Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer 1992 0.79
12 High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl 2001 0.79
13 Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplant 2009 0.78
14 Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Br J Cancer 1998 0.77
15 Successful second autologous engraftment after long duration storage of hematopoietic stem cells. Bone Marrow Transplant 2013 0.77
16 Study of the HLA-DP beta 1 locus by the polymerase chain reaction technique in patients with Hodgkin's disease. Tumori 1993 0.77
17 Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998 0.77
18 Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 1998 0.76
19 Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas. Ann Oncol 1992 0.75
20 Changing biodistribution of gallium during G-CSF treatment in non- Hodgkin's disease. Eur J Nucl Med 1999 0.75
21 Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). Int J Radiat Oncol Biol Phys 1994 0.75
22 Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 1993 0.75
23 Lack of carboplatin activity in malignant lymphomas. Eur J Cancer 1996 0.75